Clinical Trial Management Guidelines under Covid-19 – Europe

Good Clinical Practice (GCP) is referred to an internationally acclaimed ethical and scientific quality standard for designing, recording and reporting trials involving participation of human subjects. Compliance with this standard assures the protection of trial subjects and increases the credibility of clinical trial data.

The Declaration of Helsinki, developed by the World Medical Association, serves as the foundation for ethical principles that ensure full protection of clinical trial participants.

In the European Union (EU), guidance governing the conduct of clinical trials—including GCP, good manufacturing practice (GMP), and related inspections—is established in the following directives:

• Directive 2001/20/EC (Clinical Trial Directive) 
• Directive 2005/28/EC (GCP Directive)

The Heads of Medicines Agencies (HMA) platform provides key information regarding Member State activities, including:

• Guidance on managing clinical trials during the COVID‑19 pandemic 
• Instructions for sponsors on modifying trial operations and participant management during the pandemic

These documents outline measures to address pandemic‑related challenges, such as:

1. Implementing self‑isolation or quarantine procedures for trial participants 
2. Limiting participant access to hospitals or public spaces to reduce infection risk 
3. Reallocating healthcare professionals to respond to increased clinical care demands 
4. Communicating operational changes to national competent authorities

The guidance also specifies certain advice on clinical trials for treating COVID-19, including the requirement for bigger, multi-national trial protocols. This is an extension to CHMP’s call urging the EU research community to prioritize large randomized controlled clinical studies as these are supposed to generate some conclusive evidence needed to enable rapid development and approval of potential COVID-19 treatments. It has made it clear that the participation of all EU countries is a necessity in these trials (CHMP statement: A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19).

A special note that has been issued by the authority mentions that “Member States are encouraged to implement the harmonised guidance to the maximum possible extent to mitigate and slow down the disruption of clinical research in Europe during the public health crisis. At the same time, sponsors and investigators need to take into account that national legislation and derogations cannot be superseded. Member States shall complement the guidance to create additional clarity on specific national legal requirements and derogations to them.”

Because clinical trials in the EU are authorized and overseen at the national level, sponsors must verify applicable national laws and guidance that may complement—or take precedence over—the harmonized recommendations.

The Clinical Trials Expert Group (CTEG) of the European Commission endorsed the guidance, with full support from the European Medicines Agency (EMA), the Clinical Trials Facilitation and Coordination Group (CTFG) of the HMA, and the GCP Inspectors’ Working Group. Collectively, these bodies aim to ensure optimal protection for trial participants across the EU while maintaining the integrity and quality of clinical data..